CJC-1295


Overview

CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH 1-29, also called sermorelin in its unmodified form). It tells the pituitary to produce more growth hormone and is almost always discussed in two versions: with DAC (Drug Affinity Complex) and without.

The no-DAC version (Mod GRF 1-29) produces short natural pulses; the DAC version elevates GH for days at a time. The community strongly favors no DAC.

How It Works

GHRH analogues bind GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release. The modification in Mod GRF 1-29 protects the peptide from rapid enzymatic breakdown, extending its half-life from minutes to about 30 minutes — enough for a solid pulse.

The DAC difference

The DAC version binds albumin in the blood, creating a half-life of 6-8 days. This produces continuously elevated GH rather than natural pulses — a pattern associated with more side effects (water retention, tingling, insulin resistance) and less physiological rhythm.

Key Benefits

Synergy with GHRPs — combining a GHRH analogue with ipamorelin produces a GH pulse larger than either alone; this is the standard clinic stack.

Sleep and recovery — improved deep sleep is the hallmark reported benefit.

Body composition — gradual improvements in fat loss and lean tissue over months.

Anti-aging support — addresses the age-related decline in GH output.

Side Effects & Considerations

Common effects include injection site reactions, flushing, transient head rush after injection, and water retention. The DAC version more often causes numbness, tingling and sustained bloat.

Key cautions

Chronically elevated GH/IGF-1 is inappropriate with active cancer or proliferative diabetic retinopathy. Fasting glucose may rise. As with all research peptides: not approved for human use, WADA prohibited, and grey-market quality is a gamble. The no-DAC version is the defensible choice if one is made at all.

Dosage protocols

Protocol Dosage Frequency Duration Notes
No DAC / Mod GRF (anecdotal) 100 mcg 1-3 times daily 8-12 weeks Inject fasted, ideally paired with ipamorelin. Before bed is the classic timing.
With DAC 2 mg Once weekly 8-10 weeks Sustained elevation; more side effects. Less favored by the community.

Warnings

Not approved for human use. Avoid with active cancer. Prefer the no-DAC version for pulsatile release.